A Mathematical Model of Cell Cycle Progression Applied to the MCF-7 Breast Cancer Cell Line

In this paper, we present a model of cell cycle progression and apply it to cells of the MCF-7 breast cancer cell line. We consider cells existing in the three typical cell cycle phases determined using flow cytometry: the G1, S, and G2/M phases. We further break each phase up into model phases in order to capture certain features such as cells remaining in phases for a minimum amount of time. The model is also able to capture the environmentally responsive part of the G1 phase, allowing for quantification of the number of environmentally responsive cells at each point in time. The model parameters are carefully chosen using data from various sources in the biological literature. The model is then validated against a variety of experiments, and the excellent fit with experimental results allows for insight into the mechanisms that influence observed biological phenomena. In particular, the model is used to question the common assumption that a ‘slow cycling population’ is necessary to explain some results. Finally, an extension is proposed, where cell death is included in order to accurately model the effects of tamoxifen, a common first line anticancer drug in breast cancer patients. We conclude that the model has strong potential to be used as an aid in future experiments to gain further insight into cell cycle progression and cell death.

[1]  Ovide Arino,et al.  A survey of structured cell population dynamics , 1995, Acta biotheoretica.

[2]  Y. Kang,et al.  Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells , 1995, Annals of surgical oncology.

[3]  Graeme C. Wake,et al.  Modelling the flow of cytometric data obtained from unperturbed human tumour cell lines: Parameter fitting and comparison , 2005 .

[4]  R. Sutherland,et al.  Estrogen-induced Activation of Cdk4 and Cdk2 during G1-S Phase Progression Is Accompanied by Increased Cyclin D1 Expression and Decreased Cyclin-dependent Kinase Inhibitor Association with Cyclin E-Cdk2* , 1997, The Journal of Biological Chemistry.

[5]  I. Taylor,et al.  Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. , 1983, Cancer research.

[6]  K. Bystricky,et al.  Cell Cycle and Anti-Estrogen Effects Synergize to Regulate Cell Proliferation and ER Target Gene Expression , 2010, PloS one.

[7]  Ulla Holst,et al.  Estimating the variation in S phase duration from flow cytometric histograms. , 2008, Mathematical biosciences.

[8]  G. Wake,et al.  On a multicompartment age-distribution model of cell growth , 2010 .

[9]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.

[10]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[11]  Graeme Wake,et al.  A mathematical model for analysis of the cell cycle in cell lines derived from human tumors , 2003, Journal of mathematical biology.

[12]  K. Suda,et al.  G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells , 2008, Human Cell.

[13]  A. deFazio,et al.  Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. , 1995, Molecular endocrinology.

[14]  I W Taylor,et al.  Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. , 1983, Cancer research.

[15]  J. Carroll,et al.  Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. , 2002, Cancer research.

[16]  D. Dix,et al.  Expression of inducible Hsp70 enhances the proliferation of MCF-7 breast cancer cells and protects against the cytotoxic effects of hyperthermia , 2001, Cell stress & chaperones.

[17]  J. A. Hamilton,et al.  Hormonal Control of Breast Cancer Cell Cycle Progression , 1994 .

[18]  J. Carroll,et al.  Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1 , 2005, Molecular and Cellular Endocrinology.

[19]  T. Rydén,et al.  Estimating the distribution of the G(2) phase duration from flow cytometric histograms. , 2008, Mathematical biosciences.

[20]  B. Baguley,et al.  Using a stem cell and progeny model to illustrate the relationship between cell cycle times of in vivo human tumour cell tissue populations, in vitro primary cultures and the cell lines derived from them. , 2009, Journal of theoretical biology.

[21]  Paolo Ubezio,et al.  A Generalised Age- and Phase-Structured Model of Human Tumour Cell Populations Both Unperturbed and Exposed to a Range of Cancer Therapies , 2007, Bulletin of mathematical biology.

[22]  R. Sutherland,et al.  Acute effects of growth factors on T-47D breast cancer cell cycle progression. , 1993, European journal of cancer.

[23]  Graeme Wake,et al.  Modelling cell death in human tumour cell lines exposed to the anticancer drug paclitaxel , 2004, Journal of mathematical biology.

[24]  R. Sutherland,et al.  Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. , 1989, Cancer research.

[25]  R. Sutherland,et al.  Insulin/Insulin-like Growth Factor-I and Estrogen Cooperate to Stimulate Cyclin E-Cdk2 Activation and Cell Cycle Progression in MCF-7 Breast Cancer Cells through Differential Regulation of Cyclin E and p21WAF1/Cip1 * , 2001, The Journal of Biological Chemistry.